

MAR 21 2005

PTO/SB/08D (08-03)

Approved for use through 06/30/2006, OMB:0553-0131
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1-498/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/087,987
(Use as many sheets as necessary)				<i>Filing Date</i>	03/05/2002
				<i>First Named Inventor</i>	ROBERT B DICKSON
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	S. Ungar
Sheet	1	of	1	Attorney Docket Number	082137-0280712

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
		IBE ET AL., "Tumor Rejection by Disturbing Tumor Stroma Cell Interactions," J. Exp. Med., The Rockefeller University Press, Vol. 194 (No. 11), p. 1549-1559, (December 3, 2001).				
		OBERST ET AL., "Characterization of Matriptase Expression in Normal Human Tissues," The Journal of Histochemistry & Cytochemistry, The Histochemical Society, Inc., Vol. 51 (No. 8), p.1017-1025, 2003.				
		AIMES ET AL., "Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis," Thromb Haemost. Schattauer (Stuttgart), p. 561-572, (2003).				
		BOCCHETTA ET AL., "Epidemiology and molecular pathology at crossroads to establish causation: molecular mechanisms of malignant transformation," Oncogene, Vol. 23 (No. 38), p. 6484-6491, (Aug 23 2004 - ABSTRACT).				
		J.C. BARRETT, "Mechanisms of multistep carcinogenesis and carcinogen risk assessment," Environ Health Perspect., p. 9-20, (April 1993 - ABSTRACT).				
		YANG ET AL., "Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity," Cancer, Vol. 94 (No. 9), p. 2380-2392, (May 1 2002 - ABSTRACT).				
		HAIMOV-KOCHMAN ET AL., "Review of risk factors for breast cancer-what's new?," Harefuah, Vol. 141 (No. 8), p. 702-708, (August 2002 - ABSTRACT).				

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.